In news from the latest Federal Budget, migraine prevention drug Emgality (generic name galcanezumab) has now been listed on the PBS as of June 2021.
Emgality is used as a migraine preventer in adults and is used once a month by self-administered injection. The cost was previously up to $1,000 a month and will now be $41.30 a month, or $6.60 a month for concession card holders.
For many of our long-term patients who have been enrolled in previous trials of Aimovig, this will be welcome news.
If you would like to arrange an appointment with one of our practitioners to discuss whether Emgality is suitable for you, please send a referral to us from your health care provider, contact us on (08) 8340 7733 or use our contact form and our reception staff will be in touch.